Table 3.

Risk factors for VTE (univariable analysis)

Factor	No. of patients N = 1 054a	No. of VTE (%) N = 138 (13%)	OR	95% CI	P
RPLN 3.5 cm cutoffb
RPLN ≤3.5 cm	931	42 (8%)	—	—	—
RPLN >3.5 cm	378	82 (22%)	2.98	2.04, 4.34	<.001
RPLN 5 cm cutoffc
RPLN ≤5 cm	810	84 (10%)	—	—	—
RPLN >5 cm	243	54 (22%)	2.6	1.77, 3.81	<.001
Primary sited
Testicular primary	979	118 (12%)	—	—	—
Mediastinal primary	27	6 (22%)	2.16	0.78, 5.99	.14
Retroperitoneal primary	15	6 (40%)	5.76	1.97, 16.82	.001
IGCCCG Risk Classificatione
Good prognosis	693	64 (9%)	—	—	—
Intermediate prognosis	204	31 (15%)	1.72	1.08, 2.74	.02
Poor prognosis	155	43 (28%)	3.26	2.06, 5.17	<.001
LDH categoriesf
<1.5× ULN	702	61 (9%)	—	—	—
1.5‐ 5× ULN	244	50 (20%)	2.55	1.68, 2.74	<.001
5‐10× ULN	48	13 (27%)	3.61	1.78, 7.32	<.001
>10× ULN	30	9 (30%)	4.68	1.95, 11.22	.001
LDH cutofff
<5× ULN	946	111 (12%)	—	—	—
>5× ULN	78	22 (28%)	2.92	1.70‐5.02	<.001
Khorana scoreg
0‐2	882	105 (12%)	—	—	—
>3	66	20 (30%)	3.19	1.80, 5.64	<.001
Hospitalizationh
No	359	40 (11%)	—	—	—
Yes	413	64 (15%)	1.44	0.94‐2.19	.1
BSAi
<2	621	83 (13%)	—	—	—
>2	414	52 (13%)	0.9	0.62‐1.31	.58
Vascular access devicej
No	602	58 (10%)		—	—
Yes	177	51 (29%)	3.46	2.22, 5.40	<.001
Renal functionk
CrCl >75 mL/min	668	89 (13%)	—	—	—
CrCl <75 mL/min	51	16 (31%)	3.48	1.87, 6.49	<.001

^aExcludes patients who received prophylactic anticoagulation.

^bUnknown in 123 patients.

^cUnknown in 1 patient.

^dUnknown or other site in 33 patients.

^eUnknown in 2 patients.

^fUnknown in 30 patients.

^gUnknown in 106 patients.

^hUnknown in 277 patients.

ⁱUnknown in 81 patients.

^jUnknown in 275 patients.

^kUnknown in 335 patients.